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Abstract
Background: Conduction disturbances requiring permanent pacemaker implantation following tran-
scatheter aortic valve replacement (TAVR) are a common problem. Pacemaker implantation rates after 
TAVR appear to be higher compared to conventional aortic valve replacement. The aim of this study 
was to analyze whether a high annulus implantation conveys the benefit of a decreased rate of perma-
nent pacemaker implantation while being safe and successful according to Valve Academic Research 
Consortium 2 (VARC2)-criteria.
Methods: A total of 23 patients with symptomatic severe aortic valve stenosis, an aortic annulus of 
19–27 mm and at high risk for surgery were treated with the Lotus valve. In all patients the valve was 
implanted in a high annulus position via femoral access. The primary device performance endpoint was 
VARC2-defined device success after 30 days and the primary safety endpoint was the need for permanent 
pacemaker implantation.
Results: The mean age was 73.23 ± 7.65 years, 46% were female, 38% were New York Heart 
Association class III/IV at baseline. Thirty-day follow-up data were available for all patients. The 
VARC2-defined device success rate after 30 days was 22/23 (96%). 2/21 (10%) patients required  
a newly implanted pacemaker due to 3rd degree atrioventricular block. 25% of the patients developed  
a new left bundle branch block after valvuloplasty or device implantation. 21 of the 23 patients (96%) 
had no other signs of conduction disturbances after 30 days.
Conclusions: The approach of the modified implantation technique of Lotus TAVR device was safe 
and effective. The incidence of need for a permanent pacemaker following TAVR could be significantly 
reduced due to adopted implantation protocol. (Cardiol J 2017; 24, 3: 250–258)
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pacemaker, conduction disturbances, atrioventricular block
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Introduction
Transcatheter aortic valve replacement (TAVR) 
has proved to be a safe and effective treatment for 
severe aortic stenosis in appropriately selected 
high and extremely high surgical risk patients [1, 2]. 
Since its introduction in 2002 [3], TAVR has gained 
wide acceptance and implant rates have grown 
immensely [4].
In recent years an increasing number of pros-
thetic valves have entered clinical trials and routine 
practice [5–7]. Most of these devices incorporate 
novel features designed to reduce the pitfalls 
identified with current-generation devices. The 
Lotus prosthetic valve (Boston Scientific, USA) 
is a second-generation TAVR device that employs 
a novel expansion mechanism. The outer surface 
of the lower half of the frame is covered with an 
adaptive seal, which seals the frame against the 
native aortoventricular interface [7, 8]. The device 
is fully repositionable and resheathable, even in 
the completely expanded position, allowing for fine 
control and potential for removal.
The REPRISE I Trial (Repositionable Per-
cutaneous Replacement of Stenotic Aortic valve 
Through Implantation of Lotus-Valve System) 
was a proof-of-concept study with the Lotus valve 
for TAVR with a procedural success rate of 100% 
(n = 11) [9]. The REPRISE II study showed that 
the valve was successfully implanted in all patients, 
with no cases of valve embolization, ectopic valve 
deployment, or additional valve implantation. All 
repositioning (n = 26) and retrieval (n = 6) at-
tempts were successful. At 30 days, the mortality 
rate was 4.2%, and the rate of disabling stroke was 
1.7%; 1 (1.0%) patient had moderate paravalvular 
regurgitation, whereas none had severe paraval-
vular regurgitation thereby demonstrating safety 
and efficacy of this new device [10].
The occurrence of conduction abnormalities 
leading to the need for permanent pacemaker 
implantation (PPI) remains one of the most con-
cerning complications associated with TAVR, with 
an incidence ranging from 9.3% to 42% among 
patients receiving a self-expandable valve (Core- 
Valve, Medtronic, USA) [11, 12] and from 2.5% 
to 11.5% after TAVR with a balloon-expandable 
valve (Edwards valve, Edwards Lifesciences, 
USA) [13, 14]. Conduction disturbances also pose 
a well-known problem after surgical aortic valve 
replacement, with an incidence ranging from 3.2% 
to 8.5% [15, 16].
For the Lotus valve, the REPRISE I study 
showed that 36% of patients (4/11) required 
a permanent pacemaker post-procedure [9], where-
as 28.6% of patients (34/120) received a permanent 
pacemaker in the REPRISE II study [10]. A number 
of factors have been attributed as predictors of PPI, 
including depth of implantation.
The aim of this study was to analyze if a high 
annulus implantation conveys the benefit of 
a decreased rate of PPI while being safe and suc-
cessful according to the Valve Academic Research 
Consortium (VARC2)-criteria.
Methods
A total of 23 patients with symptomatic severe 
aortic stenosis were included in this study. All 
patients were treated at a single German center. 
Patients were eligible for inclusion if they had 
severe aortic stenosis based on echocardiographic 
criteria and reported symptoms attributable to 
severe aortic stenosis. Decision on interventional 
strategy, access route and selection of the device 
was done in a Heart Team session on Charité, 
Campus Virchow Klinikum.
The study was approved by the local ethics com-
mittee and all patients gave written informed consent.
Pre-procedural echocardiographic  
assessment 
Echocardiography was performed using 
a Vivid-7 machine (GE Healthcare, USA). All scans 
were assessed by an experienced echocardiolo-
gist with severity of aortic stenosis graded based 
on European Association of Echocardiography 
and American Society of Echocardiography joint 
guidelines [17].
Valve implantation
All TAVR procedures were performed in 
a hybrid operation room with patients under general 
anesthesia. Two cardiologists (F.K. and M.L.) per-
formed all procedures with both operators present 
at each procedure.
The femoral artery was used for device access 
in all cases with an 18-F Lotus Introducer (Boston 
Scientific) used for 23-mm Lotus cases and 20-F 
Lotus Introducer for those receiving a 27-mm 
Lotus valve. The femoral access was routinely 
“pre-closed” with 2 Proglide devices (Abbott Vas-
cular, Abbott Park, Illinois), and final closure was 
performed using a crossover balloon occlusion 
technique [18].
Balloon valvuloplasty was performed in 12 out 
of 23 patients (52%) under rapid ventricular pacing 
to enable maximal balloon stability. Deployment of 
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the respective devices was performed in accord-
ance with manufacturer’s guidelines and best 
practices [7, 8, 19]. Regarding the implantation 
marker of the device, Lotus valves were implanted 
in this trial as high as possible with the same pull 
and push technique described previously [7, 8]. 
The Lotus aortic bioprosthesis has a radiopaque 
marker, which should be used as a reference point 
to facilitate orientation. For regular implantation 
regime the marker should be in close proximity 
to the pigtail catheter in the aortic root. In this 
modified implantation protocol, the radiopaque 
marker was positioned above the pigtail catheter 
curve at the beginning of valve deployment. This 
ensures a higher positioning of approximately 
4 mm or less (Figs. 1, 2). Aortic regurgitation 
was assessed by aortography after final deploy-
ment. Moderate or greater aortic regurgitation, 
identified at the time of deployment was treated 
by repositioning. 
Post-procedural echocardiographic  
assessment 
All patients had a transthoracic echocardio-
graphy study performed post-procedural and at 
30 day follow-up. The post-procedural assessment 
included prosthesis function, degree and location 
of aortic regurgitation and left ventricular function. 
Prosthetic regurgitation was assessed in accord-
ance with VARC2 [20] recommendations.
Clinical review
A study investigator reviewed patients at 
the time of each echocardiogram, and continuous 
recording of atrioventricular (AV) conduction for 
72 h post procedure were performed and a detailed 
history was taken and an examination performed. 
New York Heart Association functional class was 
determined on the basis of the patient’s self-
reporting of symptoms. Rhythm monitoring was 
done continuously via monitor in an intensive care 
unit or telemetry on the cardiology ward.
Figure 1. Modified implantation technique of the Lotus aortic bioprosthesis, showing higher seating (A) versus con-
ventional implantation (B).
Figure 2. High positioning of the Lotus device. The radio- 
paque marker of the superior portion of the Lotus de-
vice is aligned with the upper curve of the pigtail cathe-
ter, which is seated in the aortic cusp (arrows).
A B
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Clinical endpoints
The primary clinical endpoint of the trial was 
VARC2-defined device success [20]. Prosthetic 
function was determined by core laboratory assess-
ment of the discharge echocardiogram. Secondary 
endpoints were all-cause and cardiovascular mor-
tality at 30 days, minor and major bleeding, minor 
and major vascular injury and due to modified 
implantation technique secondary endpoints which 
included conduction disturbances and pacemaker 
implantation rates post TAVR implantation.
Results
Within 6 months 23 patients were treated with 
a Lotus device using a modified implantation technique 
at this center. Table 1 shows baseline characteristics. 
The mean Society of Thoracic Surgeons risk of morbid-
ity or mortality score was 19.99 ± 7.69. All patients 
were discussed by the Heart Team and were consid-
ered to be high risk for surgery. Table 2 shows echo-
cardiographic assessment before the index procedure.
Procedural success and clinical outcome
Lotus valve implantation was successful in all 
patients. Ten 23 mm, nine 25 mm and four 27 mm 
Lotus valves were implanted. Partial recapture 
was necessary in 52% of the cases (12 patients). 
Clinical outcomes
According to REPRISE I and II data clinical pro-
cedural success rate and device success rate were 
100%, all devices were implanted by transfemoral 
access. Delivery, deployment, valve positioning, 
delivery system retrieval were successful in 100% 
too. In all cases intended valve performance was 
100%, no major adverse cardiac and cerebrovascular 
events (MACCE) occurred through discharge. One 
patient died at day 28 due to a pneumonia and sep-
sis in an external rehabilitation hospital and there 
were two minor strokes during the 30 day-follow 
up. There were no major vascular complications. 
Three (13%) patients experienced minor bleeding 
at the closure site, no patient required surgery or 
blood transfusions (Table 3).
Echocardiography outcome at discharge 
and at follow-up 
Echocardiographic assessment postproce-
dural showed a significant decrease in mean aortic 
gradient (before 42.09 ± 18.23 mm Hg vs. post-
procedural 13.96 ± 4.12 mm Hg, p < 0.001) and 
a significant increase in effective orifice area (before 
0.73 ± 0,13 cm2 vs. postprocedural 1.52 ± 0.25 
cm2, p < 0.001) (Tables 2, 4).
VARC2 criteria
Severe paravalvular aortic regurgitation was 
not detected in any of the patients, neither after 
the procedure nor at 30 day follow-up. No patient 
had paravalvular aortic regurgitation which was 
more than trivial (Fig. 3).
The average mean aortic valve gradient was 
13.96 ± 4.12 mm Hg and a mean aortic valve gra-
dient of more than 20 mm Hg was only observed 
in 1/23 patients after the procedure and during 
30 day follow-up (Table 4).
The mean effective orifice area after the 
procedure was 1.57 ± 0.25 cm2 and no pa-
tient/valve mismatch as defined by the VARC2 
criteria was observed (Table 4).
Table 1. Demographic data and clinical  
characteristics of the patient population.
Parameter Mean ± SD or n (%)
Age [years] 76.13 ± 8.18
Male 9 (39%)
STS Risk Score 19.99 ± 7.69
log EUROscore [%] 15.01 ± 11.52
NYHA functional class
II 8 ± 34.78
III 12 ± 52.17
IV 3 ± 13.04
Hypertension 22 (95.65%)
Diabetes 7 (30.43%)
Coronary artery disease 16 (69.57%)
History of PCI 7 ± 30.43
History of CABG 4 ± 17.39
History of atrial fibrillation 5 ± 21.74
STS — the Society of Thoracic Surgeons risk of morbidity or mor-
tality score; NYHA — New York Heart Association; PCI — percutane-
ous coronary intervention; CABG — coronary artery bypass grafting
Table 2. Key parameters evaluated at initial 
echocardiographic assessment.
Parameter Mean ±  SD
Transaortic gradient [mm Hg] 42.95 ± 18.23
Aortic velocity [m/s] 4.07 ± 0.88
Aortic valve area [cm2] 0.73 ± 0.13
Aortic root [mm] 24.87 ± 1.71
Aortic regurgitation 1.06 ± 0.73
LV-function — LVEF [%] 50.00 ± 13.84
LV — left ventricular; LVEF — left ventricular ejection fraction;  
SD — standard deviation
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Intra- and interventricular  
conduction disturbances
In the initial electrocardiogram (ECG) 19 out 
of the 22 patients (78.3%) showed sinus rhythm, 
whereas 5 of the patients (21.7%) displayed atrial 
fibrillation. The mean QRS duration before the TAVR 
was 110.8 ± 25.83 ms and 126.9 ± 19.05 ms (p > 0.05) 
at discharge. It did not change significantly at the 
30 day follow-up (QRS 125.9 ± 13.03 ms, p > 0.05). 
The mean PR duration before the TAVR was 
177.4 ± 33.84 ms and at discharge to 169.8 ± 47 ms 
(p > 0.05) and did not change significantly at the 
30 day follow-up (QRS 166.9 ± 32.05 ms, p > 0.05). 
17.4% of the patients showed a left bundle branch 
block (LBBB) before the procedure and 25% of the 
patients displayed LBBB after the TAVR (p < 0.05). 
One patient (13%) showed a right bundle branch block 
(RBBB) in the initial ECG and that patient underwent 
elective pacemaker implantation before the TAVR. 
Post-TAVR there were no new RBBB observed. 
17.4% of the patients displayed a first degree AV block 
at the initial presentation, whereas after TAVR there 
were only 15% first degree AV blocks (p > 0.05). One 
patient developed a third degree AV block after the 
TAVR and required the implantation of a permanent 
pacemaker (Fig. 4).
Statistical analysis
Continuous data were presented as mean 
± standard deviation (SD) and dichotomous data 
in percentage. Differences in continuous variables 
between two groups were analyzed using Student’s 
t-test. All statistical analyses were performed with 
Statview 5.0 (SAS Institute), SPSS 22.0 (IBM) and 
PRISM 5.0 (GraphPad). Differences were consid-
ered statistically significant when p < 0.05.
Discussion
There is growing evidence supporting the effi-
cacy and safety of TAVR as an alternative treatment 
strategy to surgical valve replacement in patients 
at higher-risk [1, 10] and its superiority to medical 
therapy in patients denying surgery [2].
Despite improvements in deployment tech-
niques, a number of limitations remained, includ-
ing vascular access complications [21, 22], the 
need for permanent pacemaker after implantation 
Table 3. Outcomes and clinical endpoint at discharge and at 30 day follow up.
At discharge  
(%)
At follow-up  
(30 days) (%)
Major adverse cardiac and cerebrovascular events 0 (0%) 1 (4.35%)
Death 0 (0%) 1 (4.35%)
Myocardial infarction < 72 h 0 (0%)
Major stroke 0 (0%) 0 (0%)
Urgent conversion to surgery or repeat procedure  
for valve-related dysfunction
0 (0%) 0 (0%)
Vascular complications 2 (8.6%)
Minor bleeding 2 (8.6%)
Acute kidney injury 0 (0%) 0 (0%)
Myocardial infarction > 72 h 0 (0%) 0 (0%)
Minor stroke or transient ischemic attack 2 (8.7%) 0 (0%)
Table 4. Key echocardiographic parameters evaluated at discharge and at 30 day follow-up.
Parameter At discharge  
± standard deviation
At follow-up (30 days)  
± standard deviation
P
Peak aortic gradient [mm Hg] 29.54 ± 11.66 28.34 ± 10.55 > 0.05
Mean aortic gradient [mm Hg] 13.96 ± 4.12 12.64 ± 3.75 > 0.05
Effective orifice area [cm2] 1.57 ± 0.25 1.62 ± 0.23 > 0.05
Left ventricular ejection fraction [%] 53.37 ± 7.79 51.91 ± 10.21 > 0.05
Aortic regurgitation 0.33 ± 0.49 0.0625 ± 0.25 > 0.05
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[11, 23], periprosthetic aortic regurgitation [24] 
and stroke [25, 26].
The Lotus valve has been shown to be highly 
efficient with high rates of procedural success, 
driven by high rates of correct positioning of a single 
device and lower rates of moderate paraprosthetic 
aortic regurgitation (PAR) [7]. The Lotus valve has 
also shown to be safe with low rates of procedural 
mortality and low rates of transprosthetic gradients 
greater than 20 mm Hg [7].
However, published data suggests that the 
Lotus valve has a higher rate of permanent pace-
maker insertion after TAVR implantation [9–11]. 
Higher rates of pacemaker implantation have been 
shown to be associated with depth of implantation 
and the size of the prosthetic device [27]. It has 
been shown that a higher seating in regard to the 
aortic annulus reduces the need for PPI [28, 29].
In this study, analysis of whether a higher 
implantation technique of the Lotus valve is safe 
Figure 4. QRS duration, new onset of bundle branch block and rate of high grade atrioventricular block (AVB) before 
and after procedure; LBBB — left bundle branch block; RBBB — right bundle branch block.
Figure 3. Procedural success as determined by VARC2 criteria.
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and successful but also, whether it decreases the 
requirement of pacemaker implantation.
Higher implantation of the Lotus valve 
shows similar efficacy and safety 
In this single-center non-randomized trial the 
modified Lotus device implantation was associated 
with high rates of procedural success (100%). This 
result is identical to the procedural success rate of 
100% reported by Gooley et al. [30] and the pro-
cedural success rate of 100% reported in both the 
REPRISE I and REPRISE II trials [9, 10].
The modified implantation technique also 
showed high VARC2-defined primary composite 
outcome of device success of 79%. These results 
are similar to the VARC2-as defined by a success 
rate of 84% reported by Gooley et al. [30] and even 
higher compared to VARC2-defined success rate 
of 60.7% reported in the REPRISE II trial [10].
The rate of moderate or severe PAR in this 
study was 0%. Again this result is similar to the 
percent of moderate to severe PAR of 0% reported 
in both the REPRISE I and REPRISE II trials [9, 10].
The observed MACCE rate in this study of 
4.35% is low and similar to the MACE rates of 9.1% 
and 4.2% reported in the REPRISE I and REPRISE 
II trials, respectively [9, 10].
Two out of the 23 patients (8.7%) had a minor 
stroke following TAVI in this study. This is slightly 
higher than the stroke rates of 1.7% reported by 
Gooley et al. [30] and the stroke rates of 0% and 
4% reported in the REPRISE I and REPRISE II 
trials, respectively [9, 10]. 
Intraventricular conduction impairment
Houthuizen et al. [31] reported that approxi-
mately 40% of patients developed a new LBBB 
after TAVR of which most persisted at follow-up, 
however without the need for pacemaker implanta-
tion. In another analysis, a proportion of AV conduc-
tion disturbances after the intervention has been 
shown to recover at 3 months of follow-up, and only 
40% of the permanent pacemaker patients for high-
degree AV block still had an AV block underlying 
their paced rhythm [32]. Without any clinical signs 
for pacemaker requirements our approach to wait 
and observe has been safe in our patient popula-
tion. Due to the relatively low sample size of these 
studies, this issue needs further investigation.
Reduced rate of AV-conduction impairment 
and therefore decreased pacemaker rates
The observed rate of AV-conduction impair-
ment of second or third degree post TAVR was 
9.5% (2/21) in this study. Subsequently, pacemaker 
implantation rate was also 9.5% (2/21) in this 
study, which is markedly lower than the previous 
published rates of 28% [30] and the rates reported 
of 36% and 28.6% in the REPRISE I and REPRISE 
II studies, respectively [9, 10].
Pre-existing RBBBs have been shown to be 
a strong predictor for higher AV-conduction impair-
ment and requirement of PPI after TAVR and it is 
usually recommended to implant pacemakers in 
those patients before the procedure [33].
Both patients requiring PPI post TAVR due 
to third degree AV conduction impairment in this 
study displayed a RBBB in the initial ECG. In both 
patients the clinical situation was critical so it was 
decided to proceed with the TAVR knowing that 
there was a high risk of postprocedural require-
ment of a PPI.
In this study 43.48% of the patients underwent 
TAVR using a 23 mm prosthetic valve, 39.13% 
using a 25 mm prosthetic valve and 17.39% using 
a 27 mm valve. For the REPRISE I trial there was 
only one valve size (23 mm) available and for the 
REPRISE II study only the 23 and 27 mm Lotus 
valve were available [9, 10]. In the study by Gooley 
et al. [30] 52% of the patient had a 23 mm Lotus 
prosthetic valve and 48% had a 27 mm prosthetic 
valve.
The risk of postoperative AV block has been 
shown to increase by 2-fold following a large valve 
implantation in a small annulus, 4-fold using Core-
Valve versus the Sapien valve [34]. Moreover, large 
meta-analyses have shown that oversizing > 4 mm 
is a major risk factor for PPI following TAVI [35]. 
The smaller bioprosthetic valves used in our study 
might therefore have contributed to the lower rate 
of PPI required in our patient population.
The implantation technique used during the 
REPRISE trials was markedly deeper within the 
left ventricular outflow tract comparable to the 
first techniques used for the CoreValve. Piazza et 
al were able to show that implantation depth was 
10.3 mm in those patients who required a PPI, 
versus 5.5 mm in those without PPI requirement 
[36]. Similar findings were shown for implantation 
of balloon-expandable TAVR [28].
The potential pitfalls of higher implantation 
technique are obstruction of the coronary arter-
ies and a higher risk of valve dislocation thereby 
making a second prosthetic valve implantation 
necessary.
A low position of the coronary ostia with re-
spect to the aortic annulus has been highlighted as 
one of the most important factors contributing to 
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obstruction of the coronary ostia following TAVR, 
and it has been suggested that a coronary ostia 
height of ≤ 10 mm increases the risk of coronary 
obstruction during TAVR [37–39].
The principal findings of the present study are:
 — higher implantation of the Lotus valve shows 
similar efficacy and safety characteristics 
compared to the lower implantation technique 
described in the REPRISE trials;
 — TAVI using the Lotus bioprothetic valve im-
pairs intraventricular conduction resulting in 
a new left bundle block in 25% of the patients;
 — higher graded AV-conduction abnormalities 
following TAVR implantation can be mark-
edly reduced by exact valve sizing and a high 
implantation technique relative to the aortic 
annulus thereby decreasing the pacemaker 
rates to a level comparable to TAVR with 
a balloon expanding valve or surgical aortic 
valve replacement. 
Conclusions
The approach of a high implantation technique 
of Lotus TAVR devices was safe and effective. The 
incidence of the need for a permanent pacemaker 
following TAVR could be significantly reduced due 
to the modified implantation protocol.
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